Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial

Degaga TS., Pasaribu AP., Tripura R., Ghanchi N., Rajasekhar M., Adhikari B., Ley B., Bamboro SA., Jabbar FA., Hasibuan N., Tego TT., Zehra S., Qurashi B., Mnjala H., Lee G., Li P., Kazi AM., Safitri W., Yulita Y., Siagian DSP., Syahputra D., Hadi H., Muhammad T., Ibrahim A., Syed N., Dost K., Puspitrasari AM., Kariodimedjo PP., Rai A., Rumaseb A., Sutanto E., Ean M., Khan A., Sokha M., Commons RJ., Weston S., Noviyanti R., Peto T., Callery JJ., Ali U., Mehmood T., Dondorp A., Devine A., Setiawan E., Mwaura M., Cassidy-Seyoum S., Temesgen R., Abate DT., Erjabo EB., Gessa GG., Kiros FG., Usmani MI., Raza A., Woyessa A., Hailu A., Simpson JA., Karahalios A., Beg MA., von Seidlein L., Dysoley L., Auburn S., Price RN., Thriemer K.

DOI

10.1016/s1473-3099(25)00729-7

Type

Journal article

Publisher

Elsevier BV

Publication Date

2026-02-01T00:00:00+00:00

Permalink More information Close